Publication | Closed Access

Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers

Hematological MalignancyGemtuzumab OzogamicinHealth SciencesMultidrug Resistance ModifiersMedicineImmunologyHematologyMyeloid NeoplasiaPharmacotherapyAnti-cancer AgentReduced EffectPharmacologyDrug Resistance